Drug Manufacturers – Major

(PFE) Pfizer Halts Inotuzumab Study

Pfizer Inc. (PFE) recently faced a pipeline setback with the company discontinuing a late-stage study being conducted with its oncology candidate, inotuzumab ozogamicin.

The randomized, open-label, two-arm phase III study was...

17Sep2013 | | Comments Off on (PFE) Pfizer Halts Inotuzumab Study | Continued

(IPXL) Impax Laboratories Launches Generic Zomig

Impax Laboratories, Inc. (IPXL) recently announced that it has launched its authorized generic version of AstraZeneca’s (AZN) Zomig (zolmitriptan) tablets and...

10Sep2013 | | Comments Off on (IPXL) Impax Laboratories Launches Generic Zomig | Continued

(AZN) Data on AstraZeneca’s Naloxegol

AstraZeneca (AZN) recently presented data on naloxegol (25 mg once daily) from two pivotal phase III studies (KODIAC-04 and -05) at the Digestive Disease Week (DDW) meeting. Top-line results from this study were initially presented...

9Sep2013 | | Comments Off on (AZN) Data on AstraZeneca’s Naloxegol | Continued

(ABT) Abbott Laboratories Announces CE Mark for Xpedition 48 Stent System

Abbott Laboratories (ABT) recently announced that it received CE Mark in Europe for its drug eluting stent – Xience Xpedition 48 Everolimus Eluting Coronary Stent System.

Xience Xpedition 48 is the latest addition to Abbott...

21Aug2013 | | Comments Off on (ABT) Abbott Laboratories Announces CE Mark for Xpedition 48 Stent System | Continued

(GSK) UCB Presents Study on Restless Leg Syndrome

UCB (UCBJF) recently presented data from a study showing the effect of Neupro on cardiovascular measures in patients with restless legs syndrome (RLS).

The double-blind, placebo-controlled study showed reduction in total nocturnal...

20Aug2013 | | Comments Off on (GSK) UCB Presents Study on Restless Leg Syndrome | Continued

(MRK) Merck Enters into Strategic Deal

In an attempt to boost shareholders’ value, Merck & Co. Inc. (MRK) – the N.J. based major drug manufacturer – entered into an agreement with The Goldman Sachs Group, Inc. (GS)...

13Aug2013 | | Comments Off on (MRK) Merck Enters into Strategic Deal | Continued

(SNY) Sanofi and Regeneron Pharmaceuticals Dupilumab Data Published

Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) recently announced that positive data from a phase IIa study evaluating dupilumab (REGN668/SAR231893)...

4Aug2013 | | Comments Off on (SNY) Sanofi and Regeneron Pharmaceuticals Dupilumab Data Published | Continued

(NVS) Positive Data on Novartis’ Afinitor

Novartis (NVS) recently announced positive results on Afinitor, from a phase III trial, BOLERO-3. The study is evaluating Novartis’ Afinitor plus Roche’s (RHHBY)...

23Jul2013 | | Comments Off on (NVS) Positive Data on Novartis’ Afinitor | Continued

(AZN) Roche’s Tarceva Earns US Food and Drug Administration Approval

Roche (RHHBY) recently announced that the US Food and Drug Administration (FDA) has approved Tarceva (erlotinib) tablets for the first line treatment of patients suffering from metastatic non-small cell lung cancer (NSCLC).

Tarceva...

14Jun2013 | | Comments Off on (AZN) Roche’s Tarceva Earns US Food and Drug Administration Approval | Continued

(BMY) Bristol-Myers Squibb Company Earns Good News From FDA

Bristol-Myers Squibb Company (BMY) recently received positive news from the US Food and Drug Administration (FDA) when the US regulatory authority approved the pharma major’s HIV drug Sustiva for treating children between three months...

18May2013 | | Comments Off on (BMY) Bristol-Myers Squibb Company Earns Good News From FDA | Continued

(GSK) GlaxoSmithKline’s Trametinib Delayed

Recently, GlaxoSmithKline (GSK) announced that the US Food and Drug Administration (FDA) has extended the review period for Glaxo’s oncology candidate, trametinib, by three months. A final decision from the FDA on the marketing application...

16May2013 | | Comments Off on (GSK) GlaxoSmithKline’s Trametinib Delayed | Continued

(SNY) Sanofi Earnings Plummet – Outlook Maintained

Sanofi (SNY) reported first quarter 2013 business earnings of 81 cents per American Depository Share (ADS), below the Zacks Consensus Estimate of 89 cents. Earnings were down 29.0% at constant exchange rates (CER) from the year-ago...

16May2013 | | Comments Off on (SNY) Sanofi Earnings Plummet – Outlook Maintained | Continued

(AEGR) Aegerion Pharmaceuticals Loss Narrower Than Expected

Aegerion Pharmaceuticals, Inc. (AEGR) reported first quarter 2013 net loss per share of 64 cents, narrower than the Zacks Consensus Estimate of a loss of 72 cents, but wider than the year-ago loss of 51 cents.

Net product sales...

15May2013 | | Comments Off on (AEGR) Aegerion Pharmaceuticals Loss Narrower Than Expected | Continued

(IPXL) Impax Laboratories Beats Earnings Estimate

Impax Laboratories Inc.’s (IPXL) first quarter 2013 adjusted earnings of 37 cents per share were above the Zacks Consensus Estimate of 23 cents but below the year-ago earnings of 53 cents per share.

Quarter in Details

Total...

15May2013 | | Comments Off on (IPXL) Impax Laboratories Beats Earnings Estimate | Continued

(MRK) Merck & Company Joins Forces With Bristol-Myers Squibb on Hepatitis C Virus Candidates

Merck & Co. Inc. (MRK) recently joined forces with Bristol-Myers Squibb (BMY) to conduct a phase II study with their hepatitis C virus (HCV) candidates. The study will evaluate the safety and efficacy of a once-daily oral combination...

14May2013 | | Comments Off on (MRK) Merck & Company Joins Forces With Bristol-Myers Squibb on Hepatitis C Virus Candidates | Continued

(AZN) AstraZeneca Inks Biomarker Discovery Deal

AstraZeneca (AZN) recently announced that it has entered into an agreement with UK-based company, Oxford Cancer Biomarkers Ltd. As per the terms of the agreement, Oxford Cancer Biomarkers Ltd. will work on an AstraZeneca oncology candidate...

9May2013 | | Comments Off on (AZN) AstraZeneca Inks Biomarker Discovery Deal | Continued

(LLY) Eli Lilly and Company Sees Positive Data on Diabetes Candidate

Eli Lilly and Company (LLY) recently announced top-line data on its type II diabetes candidate, dulaglutide. The company said that dulaglutide met its primary endpoint in two phase III studies (AWARD-2 and AWARD-4) which are a part...

3May2013 | | Comments Off on (LLY) Eli Lilly and Company Sees Positive Data on Diabetes Candidate | Continued

(ABT) Abbott Laboratories Launches Automated Solution

Abbott Laboratories (ABT) recently announced that the company has launched ACCELERATOR a3600 – its next-generation track system to increase efficiency in laboratories.

A laboratory automation track system, ACCELERATOR a3600...

2May2013 | | Comments Off on (ABT) Abbott Laboratories Launches Automated Solution | Continued

(PFE) Grading the First Quarter Earnings Season – Earnings Preview

Grading the Q1 Earnings Season

We have crossed the halfway mark in the Q1 earnings season, with results from 271 S&P 500 companies already out (as of Friday, April 26th). Please note that these 271 companies are more than just 54.2% of the index’s total membership –...

2May2013 | | Comments Off on (PFE) Grading the First Quarter Earnings Season – Earnings Preview | Continued

(NVS) Theravance – Glaxo Drug to Face FDA Panel

The US Food and Drug Administration (FDA) recently released briefing documents ahead of the review by its Pulmonary-Allergy Drugs Advisory Committee of the New Drug Application (NDA) of Theravance/Glaxo’s (THRX/

27Apr2013 | | Comments Off on (NVS) Theravance – Glaxo Drug to Face FDA Panel | Continued

(JNJ) BioLineRx to Start BL-8040 Study

BioLineRx (BLRX) recently received approval in the US for the initiation of a multi-center, open-label phase IIa study on BL-8040. BioLineRx is looking to develop BL-8040 for the treatment of acute myeloid leukemia (AML) and other...

27Apr2013 | | Comments Off on (JNJ) BioLineRx to Start BL-8040 Study | Continued

(JNJ) Will Johnson & Johnson Miss on Earnings?

Johnson & Johnson (JNJ) is scheduled to report its first quarter 2013 results on Apr 16, 2013 before the opening bell.

Last quarter, the company posted a 1.71% positive surprise. Let’s see how things are shaping up prior...

23Apr2013 | | Comments Off on (JNJ) Will Johnson & Johnson Miss on Earnings? | Continued

(MRK) Roche Teams Up with Ascletis

Roche (RHHBY) recently announced that it has entered into a collaboration agreement with Ascletis to develop and commercialize Roche’s candidate danoprevir in China for treating patients suffering from hepatitis-c virus (HCV).

The...

23Apr2013 | | Comments Off on (MRK) Roche Teams Up with Ascletis | Continued

(GSK) GlaxoSmithKline’s Flu Vaccine Approved

GlaxoSmithKline(GSK) recently announced the receipt of marketing authorization for its four-strain seasonal influenza vaccine in Germany and the UK. The vaccine will be marketed as Influsplit Tetra in Germany and Fluarix Tetra in the...

18Apr2013 | | Comments Off on (GSK) GlaxoSmithKline’s Flu Vaccine Approved | Continued

(SNY) Sanofi/Transgene Inks Immunotherapy Deal

Sanofi (SNY) recently entered into a collaboration Transgene for the production of immunotherapy products and creating of an industrial platform for the same. The platform will include Transgene’s candidates.

Sanofi and Transgene,...

11Apr2013 | | Comments Off on (SNY) Sanofi/Transgene Inks Immunotherapy Deal | Continued

(MRK) Pharma & Biotech Stock Outlook – Apr 2013 – Zacks Analyst Interviews

The pharmaceutical industry has been showing signs of recovery from one of the biggest patent cliffs in recent times. The last few quarters saw major blockbusters like Merck’s (MRK) Singulair, Pfizer’s (PFE)...

7Apr2013 | | Comments Off on (MRK) Pharma & Biotech Stock Outlook – Apr 2013 – Zacks Analyst Interviews | Continued

(NVS) Novartis Drug Candidate Earns Good News

Novartis (NVS) recently announced that the US Food and Drug Administration (FDA) rendered Breakthrough Therapy designation to its pipeline candidate LDK378.

The Breakthrough Therapy designation includes all the features involved...

4Apr2013 | | Comments Off on (NVS) Novartis Drug Candidate Earns Good News | Continued

(AZN) AstraZeneca to Revamp Research and Development Structure

AstraZeneca (AZN) recently announced that it plans to initiate strategic reforms in its research and development (R&D) segment. As per proposed plans, the company’s R&D activities will be primarily centered in three facilities...

1Apr2013 | | Comments Off on (AZN) AstraZeneca to Revamp Research and Development Structure | Continued

(NVS) Novartis Announces Positive Drug Approval News

Novartis (NVS) recently announced that the European Commission (EC) has approved its drug llaris (canakinumab, ACZ885) for an additional indication. The EC cleared llaris for treating adults suffering from gouty arthritis (gout) –...

13Mar2013 | | Comments Off on (NVS) Novartis Announces Positive Drug Approval News | Continued

(SNY) Sanofi Diabetes Drug Under FDA Review

Sanofi (SNY) recently announced that the US Food and Drug Administration (FDA) has accepted the marketing application of its type II diabetes candidate, lixisenatide. The company is looking to get lixisenatide approved for the treatment...

2Mar2013 | | Comments Off on (SNY) Sanofi Diabetes Drug Under FDA Review | Continued